The Alterations of Metabolic Adipo-myokines and Body Composition in End Stage Lung Cancer

Recruiting

• Conditions: Lung Cancer Metastatic

• Registration Number: NCT06060262
• Lead Sponsor: Chang Gung Memorial Hospital

Brief Summary

The investigators conduct this prospective study and wish to elucidate the association of serial change of body composition, serum adipo-myokines and adverse effect of chemotherapy and lung cancer prognosis

Detailed Description

Recently, the skeletal muscle was viewed as having biochemical function in additional to traditional biomechanical function. What's more important is that muscles could synthesize and release adipo-myokines during contraction. The adipo-myokines can affect muscle regeneration, muscle atrophy, muscle mass, autophagy, fatty acid oxidation and mitochondrial biosynthesis.Studies have also found that exercise can promote the function of macrophages and regulate both pro-inflammatory and anti-inflammatory phenotypes, helping the body to establish a stable immune balance.

Since body composition can illustrate malnutrition status and cancer cachexia present, and body composition can be affected by serum adipo-myokines level. Therefore, the investigators conduct this study and wish to see the association of serial body composition and serum adipo-myokines changes with lung cancer clinical outcomes and adverse effect of any anti-cancer regimen.

Study Timeline

• Study Start: 2023-02-02
• Status Verified: 2023-09
• Study First Submitted: 2023-09-24
• Study First Submitted QC: 2023-09-24
• Last Update Submitted: 2023-09-24
• Study First Posted: 2023-09-29
• Last Update Posted: 2023-09-29
• Primary Completion: 2025-11-30
• Study Completion: 2025-11-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

1. Diagnosis of lung cancer stage III to stage IV
2. Adults over 20 years old
3. Daily performance status of 0- 2

Exclusion Criteria

1. Cardiac stents or pacemakers

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of white blood cell change among before, during and after cancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of white blood cell count among week 0, week 4 and week 12
Percentage of body fat change among before, during and after cancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of percentage of body fat among week 0, week 4 and week 12
Percentage of total body water change among before, during and after cancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of total body water percentage among week 0, week 4 and week 12
Percentage of soft lean mass change among before, during and after cancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of soft lean mass percentage among week 0, week 4 and week 12
Concentration of plasma CEA change among before, during and after cancer therapy	week 0, week 4 and week 12 after cancer theraphy	assessing the change of plasma CEA concentration among week 0, week 4 and week 12
Concentration of plasma albumin change among before, during and after cancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of plasma albumin concentration among week 0, week 4 and week 12
Concentration of plasma myostatin change among before, during and after cancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of plasma myostatin concentration among week 0, week 4 and week 12
Concentration of plasma FSTL-1 change among before, during and after cancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of plasma FSTL-1 concentration among week 0, week 4 and week 12
Concentration of plasma IL-6 change among before, during and aftercancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of plasma IL-6 concentration among week 0, week 4 and week 12
Concentration of plasma irisin change among before, during and after cancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of plasma irisin concentration among week 0, week 4 and week 12
Concentration of plasma adiponectin change among before, during and after cancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of plasma adiponectin concentration among week 0, week 4 and week 12
Concentration of plasma MCP-1 change among before, during and after cancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of plasma MCP-1 concentration among week 0, week 4 and week 12
Concentration of plasma aquaporin change among before, during and after cancer therapy	week 0 , week 4 and week 12 after cancer theraphy	assessing the change of plasma aquaporin concentration among week 0, week 4 and week 12

Trial Locations

Locations (1)

Kaohsiung Chang Gung Memorial Hospital; 🇨🇳 Kaohsiung City, Taiwan